Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Locally Advanced NSCLC”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT04139317
What this trial is testing

Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50%

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Novartis Pharmaceuticals 76
Large-scale testing (Phase 3)WithdrawnNCT06093503
What this trial is testing

Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein

Who this might be right for
Non-Small Cell Lung Cancer
AbbVie
Testing effectiveness (Phase 2)Looking for participantsNCT06362369
What this trial is testing

Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

Who this might be right for
Advanced CancerAdvanced Solid TumorMelanoma+15 more
7 Hills Pharma, LLC 126
Testing effectiveness (Phase 2)Study completedNCT03989115
What this trial is testing

Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC

Who this might be right for
Solid Tumor
Revolution Medicines, Inc. 113
Testing effectiveness (Phase 2)Looking for participantsNCT07034391
What this trial is testing

A Study Evaluating the Efficacy of PD-1 Inhibitor Combined With Denosumab and Chemotherapy in Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Patients With Driver Gene-Negative Status

Who this might be right for
Non-Small Cell Lung Cancer
China Medical University, China 40
Testing effectiveness (Phase 2)Looking for participantsNCT07175220
What this trial is testing

Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects

Who this might be right for
Locally Advanced or Metastatic Non-small Cell Lung Cancer
Jiangsu HengRui Medicine Co., Ltd. 200
Early research (Phase 1)Study completedNCT02443324
What this trial is testing

Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer

Who this might be right for
Gastric AdenocarcinomaAdenocarcinoma of the Gastroesophageal JunctionNon-small Cell Lung Cancer+2 more
Eli Lilly and Company 175
Not applicableUnknownNCT04741633
What this trial is testing

Multi Dimensional Precise Exploration of Immunoconsolidation Therapy for Locally Advanced NSCLC After Chemo-radiotherapy

Who this might be right for
NSCLCChemoradiotherapyctDNA
Fudan University 25
Large-scale testing (Phase 3)Looking for participantsNCT07005102
What this trial is testing

Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
AbbVie 854
Testing effectiveness (Phase 2)UnknownNCT06463171
What this trial is testing

Phase II Trial of Almonertinib Plus Lastet for EGFR+ Non-small Cell Lung Cancer

Who this might be right for
Lung Cancer Non-small Cell Stage IV
Shanghai Pulmonary Hospital, Shanghai, China 60
Large-scale testing (Phase 3)Looking for participantsNCT07361510
What this trial is testing

Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb 750
Not applicableStudy completedNCT02285361
What this trial is testing

GIOTRIF rPMS in Korean Patients With NSCLC

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 1,272
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06747169
What this trial is testing

Efficacy and Safety of Sintilimab Combined with Nab-PP Plus Rh-endostatin in Locally Advanced/advanced and Recurrent Metastatic Squamous Non-small Cell Lung Cancer: a Single-arm, Multicenter Clinical Study

Who this might be right for
Squamous Non-Small Cell Lung Cancer SqNSCLC
Jian-Guo Zhou, MD, PhD 32
Large-scale testing (Phase 3)Looking for participantsNCT07362459
What this trial is testing

Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer.

Who this might be right for
Non-Small Cell Lung Carcinoma (NSCLC)
Sinocelltech Ltd. 246
Large-scale testing (Phase 3)Study completedNCT02044380
What this trial is testing

Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 14
Large-scale testing (Phase 3)Not Yet RecruitingNCT07816380
What this trial is testing

A Phase III Study to Evaluate the Efficacy and Safety of JYP0322 in Previously Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)
Guangzhou JOYO Pharma Co., Ltd 216
Testing effectiveness (Phase 2)Ended earlyNCT00378573
What this trial is testing

Multicenter Evaluation of Docetaxel, Gemcitabine, and Bevacizumab Combination Followed by Bevacizumab Alone in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Sanofi 17
Early research (Phase 1)Study completedNCT05954871
What this trial is testing

Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer

Who this might be right for
Colorectal CancerNon-Small Cell Lung Cancer
Genentech, Inc. 10
Testing effectiveness (Phase 2)Ended earlyNCT01664663
What this trial is testing

Phase II Randomized Study on Locally Advanced NSCLC Escalated Dose on Individual Basis Treatment With Radiochemotherapy

Who this might be right for
Non Small Cell Lung CancerLocally Advanced Disease
Ass. Prof. Jan Nyman 37
Large-scale testing (Phase 3)Active Not RecruitingNCT04538664
What this trial is testing

Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC 308
Next Page